Strong top-line Phase III data for Pfizer's latest JAK inhibitor

15 May 2019

Breakthrough Therapy- designated abrocitinib, a JAK1 blocker under development by Pfizer (NYSE: PFE), has passed a Phase III test with flying colors.

All primary and secondary endpoints were met in the trial, which tested the oral therapy, also known as PF-04965842, in people over the age of 12 with moderate to severe atopic dermatitis (AD).

Top-line results showed that by week 12 the percentage of patients meeting efficacy goals was higher than placebo by a statistically-significant margin, at both dosage levels.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK